Provided by Tiger Fintech (Singapore) Pte. Ltd.

Design Therapeutics, Inc.

5.26
+0.11002.14%
Volume:176.51K
Turnover:923.76K
Market Cap:299.55M
PE:-4.70
High:5.28
Open:5.20
Low:5.11
Close:5.15
52wk High:7.77
52wk Low:2.60
Shares:56.95M
Float Shares:26.28M
Volume Ratio:1.23
T/O Rate:0.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1191
EPS(LYR):-0.8763
ROE:-26.77%
ROA:-19.02%
PB:1.41
PE(LYR):-6.00

Loading ...

Director William Arsani Reports Disposal of Common Shares of Design Therapeutics Inc

Reuters
·
Aug 15

RBC Capital Sticks to Their Hold Rating for Design Therapeutics (DSGN)

TIPRANKS
·
Aug 08

Design Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Design Therapeutics Q2 net loss misses expectations

Reuters
·
Aug 08

Design Therapeutics Q2 Basic EPS USD -0.34

Reuters
·
Aug 08

Design Therapeutics Inc. Reports Q2 2025 Net Loss of $19.1 Million; R&D Expenses at $15.7 Million

Reuters
·
Aug 08

Design Therapeutics Highlights Progress Across Lead Genetac® Programs and Reports Second Quarter 2025 Financial Results

THOMSON REUTERS
·
Aug 08

Press Release: Design Therapeutics Highlights Progress Across Lead GeneTAC(R) Programs and Reports Second Quarter 2025 Financial Results

Dow Jones
·
Aug 08

Design Therapeutics Inc expected to post a loss of 33 cents a share - Earnings Preview

Reuters
·
Aug 01

Design Therapeutics Confirms Directors at Annual Meeting

TIPRANKS
·
Jun 13

Design Therapeutics Inc. Concluded Annual Stockholder Meeting

Reuters
·
Jun 13

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA), Johnson & Johnson (JNJ) and Design Therapeutics (DSGN)

TIPRANKS
·
Jun 09

RBC Capital Keeps Their Hold Rating on Design Therapeutics (DSGN)

TIPRANKS
·
Jun 04

Design Therapeutics announces first FA patient dosed in RESTORE-FA trial

TIPRANKS
·
Jun 04

Design Therapeutics Faces FDA Clinical Hold on IND Application for U.S. Expansion of RESTORE-FA Trial

Reuters
·
Jun 04

Design Therapeutics Inc. Files Initial Beneficial Ownership Statement for Chris Storgard, Chief Medical Officer

Reuters
·
May 24

Piper Sandler Sticks to Its Buy Rating for Design Therapeutics (DSGN)

TIPRANKS
·
May 08

BRIEF-Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing

Reuters
·
May 08

Design Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

BRIEF-Design Therapeutics Q1 Basic EPS USD -0.31

Reuters
·
May 08